Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Galmed Pharmaceuticals ( (GLMD) ) is now available.
Galmed Pharmaceuticals Ltd. announced a Special General Meeting of Shareholders scheduled for August 14, 2025, to discuss and vote on increasing the company’s authorized share capital. This strategic move aims to provide the company with the flexibility to raise additional capital and pursue future business opportunities, potentially impacting its financial strategy and market positioning.
Spark’s Take on GLMD Stock
According to Spark, TipRanks’ AI Analyst, GLMD is a Underperform.
Galmed Pharmaceuticals faces significant financial challenges, with no revenue and continuous losses, which heavily impact its stock score. Poor technical indicators and negative valuation metrics further weigh down the score. The strong equity position offers some support but is overshadowed by the lack of operational efficiency and profitability.
To see Spark’s full report on GLMD stock, click here.
More about Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development of oral therapies for the treatment of liver diseases. The company is primarily involved in advancing its lead compound, Aramchol, for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-related disorders.
Average Trading Volume: 1,823,797
Technical Sentiment Signal: Sell
Current Market Cap: $4.22M
For an in-depth examination of GLMD stock, go to TipRanks’ Overview page.